Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Active:	Yes
Cancer Type:	Multiple Myeloma	NCT ID:	NCT04126200
Trial Phases:	Phase I Phase II	Protocol IDs:	208887 (primary) NCI-2020-01127
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	GlaxoSmithKline
NCI Full Details:	http://clinicaltrials.gov/show/NCT04126200

Summary

B-cell maturation antigen (BCMA) is a target present on tumor cells in participants with
multiple myeloma. Belantamab mafodotin (GSK2857916); is an antibody-drug conjugate (ADC)
containing humanized anti-BCMA monoclonal antibody (mAb). This is a phase I/II, randomized,
open-label, platform study designed to evaluate the effects of belantamab mafodotin in
combination with other anti-cancer drugs in participants with relapsed/refractory multiple
myeloma. The Platform design incorporates a single master protocol, where multiple treatment
combinations, as sub-studies, will be evaluated simultaneously.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.